BREAKING: Shuren Steps Down As CDRH Director

The US FDA device center head is retiring after 28 years in the federal sector and 15 at the helm of CDRH. Deputy center director Michelle Tarver will step in as acting head.

CDRH Director Jeff Shuren in his office
• Source: Ferdous Al-Faruque

Jeff Shuren, the longtime director of the Center for Devices and Radiological Health at the US Food and Drug Administration, announced plans to retire in an all-staff email Tuesday afternoon.

Shuren has led CDRH since 2009. During his time at the helm, he has overseen key initiatives including an overhaul of the clinical trials program, the breakthrough devices program, the establishment of the Digital Health Center of Excellence, and the creation of the Office of Product Evaluation and Quality to support the total product life cycle regulatory approach. He was also key in standing up the International Device Regulators Forum and the Medical Device Innovators Consortium. (Also see "Podcast: A Chat With Jeff Shuren – FDA Device Center Chief Worries About Agency Staffing; Talks MDUFA V, Pandemic, More" - Medtech Insight, 28 June, 2021.)

According to his email, Shuren initially planned to retire in 2020 but chose to stay through the COVID-19 pandemic rather than leave during a crisis.

“This was not an easy decision for me to make because CDRH has been my home ... But it is the right decision for our center, and for me. I have my own new worlds still to explore.” -- Jeff Shuren

“Today, the pandemic is in our rearview mirror, our center is not only back on track, but I think better positioned and stronger than ever before, and our current vision has been achieved,” Shuren wrote. “This was not an easy decision for me to make because CDRH has been my home and you have been, and will continue to be, part of my family. But it is the right decision for our center, and for me. I have my own new worlds still to explore.”

He will officially step down on 28 July, when he will hand the reins to current deputy center director Michelle Tarver. The timing was chosen to allow Tarver full oversight of the upcoming Medical Device User Fee Amendment (MDUFA VI) negotiations. However, Shuren will remain at the FDA for some months to help Tarver transition into the directorate.

In an all-staff email, FDA commissioner Robert Califf described Shuren as “a catalyst for the modernization of medical device regulation and innovator in every sense of the word.”

Shuren's work at CDRH included a strong focus on speeding the path to access for medical devices in the US, which often lagged Europe in device authorizations at the time. In 2023, the center authorized the highest number of innovative devices in its 48-year history.

Trade group AdvaMed expressed its thanks.

“Jeff understood the critical role a regulator plays in the innovation ecosystem, knowing how to balance the ultimate goal of medical device safety and effectiveness with the important goal of spurring innovations that improve and save lives,” said AdvaMed president and CEO Scott Whitaker. “He saw AdvaMed and the medtech industry we represent as partners in addressing patients’ needs, and we hope his leadership serves as a model for all future directors of the CDRH.”

Michelle Tarver
Michelle Tarver • Source: Michelle Tarver

Shuren is the third high-ranking CDRH official to retire in the last year. Office of In Vitro Devices director Timothy Stenzel stepped down at the end of 2023, while OPEQ head William Maisel announced retirement plans in February.

Tarver Prepares To Take Charge

Incoming acting director Michelle Tarver isn’t a new face at the agency: Shuren’s email notes that she joined CDRH “just a few weeks” before he did in summer 2009. He went on to throw his full support to the new acting director, describing her as “truly wonderful as a person, a colleague, a friend, and a leader.”

Tarver worked in CDRH’s Office of Surveillance and Biometrics and the Office of Device Evaluation before becoming deputy director of the office of strategic partnerships and technology innovation. Her role included oversight of disaster preparedness and response, digital health, conformity standards development, and transformative products. In July 2023, Tarver moved on and became the deputy center director for transformation where she has facilitated the development, implementation, and direction of CDRH’s transformative projects and initiatives, including Home as a Health Care Hub.

Tarver holds a bachelor’s degree in biochemistry from Spelman College in Atlanta, a doctor of medicine from The Johns Hopkins University School of Medicine, and a Ph.D. in clinical epidemiology from The Johns Hopkins University Bloomberg School of Public Health. She is an epidemiologist and board-certified ophthalmologist who continues to treat patients.

More from Regulation

EU Pushes Faster Route For Innovative And Orphan Devices

 

Existing legislation already offers a route, albeit rarely used, for orphan and innovative devices to reach the market more quickly. It should be used more; manufacturers and notified bodies do not need to wait for official changes to the EU’s medtech regulations.

European Health Data Space: Commission And Industry’s Key Principles And Priorities

 

The European Commission has published a 44-page EHDS Q&A while industry has issued a joint paper emphasizing the importance of a stakeholder forum just as the EHDS Regulation is published and is due to enter into force.

HIMSS 2025: Interview with Aneesh Chopra, Arcadia’s Chief Strategy Officer, About The Future Of Health Data, Interoperability, AI

 
• By 

Medtech Insight sat down with Arcadia's chief strategy officer Aneesh Chopra to discuss interoperability, industry standards and the future of health care data and AI.

UK MHRA Holds 2025 Device Registration Fee Increase

 
• By 

Most fees and fee uplifts proposed by the UK MHRA to begin in April 2025 will be implemented on schedule. A general 8.85% increase will be applied to all statutory fees, but the new medical devices registration fee is subject to ongoing review and/or alternative options.

More from Policy & Regulation

More FDA Transitions: CDRH Deputy Director Out, New Chief of Staff And General Counsel In

 
• By 

The US FDA is seeing more staff turnover this week, with CDRH deputy director for science Douglas Kelly announcing his departure while the agency gets a new chief counsel and chief of staff.

Dexcom Eyes US FDA Clearance For 15-Day CGM, But Insurance Coverage Remains Uncertain

 
• By 

Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.

US Federal Trade Commission Challenges Surmodics-Biocoat Merger Over Antitrust Concerns

 
• By 

A planned merger between medical device coating manufacturers Surmodics and Biocoat is facing an antitrust lawsuit from the US Federal Trade Commission. The FTC believes the move would create an illegal monopoly.